Skip to main content
SpringerLink
Log in

Adalimumab worth its cost in early RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Davies A, Cifaldi MA, Segurado OG, Weisman MH.Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. The Journal of Rheumatology 36: 16-25, No. 1, Jan 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adalimumab worth its cost in early RA. Pharmacoecon. Outcomes News 573, 4 (2009). https://doi.org/10.2165/00151234-200905730-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905730-00012

Keywords

Search

Navigation